ASCO GU 2025: Combination Therapy with Cabozantinib and Atezolizumab Shows Promise for Advanced Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNew Study Reveals Key Factors That Influence How Quickly Prostate Cancer Becomes Resistant to Hormone Therapy
/0 Comments/in Retrospective studies/by MaxASCO GU 2025: Continuous ADT Remains Superior to Intermittent Therapy in Metastatic Hormone-Sensitive Prostate Cancer
/0 Comments/in Retrospective studies/by MaxASCO GU 2025: Lu-PSMA Therapy Outperforms Cabazitaxel in Advanced Prostate Cancer, Real-World Evidence
/0 Comments/in Retrospective studies/by MaxNewsletter 7/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! This time, I welcome you with a haunting photo from the Venice Carnival, which has just begun. As many of you know, last week was ASCO GU 2025, and there’s a lot to cover. I’ve reviewed around 200 of the 400+ prostate cancer […]
Undetectable PSA Nadir Linked to Better Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: Real-World Data from IRONMAN Registry
/0 Comments/in Retrospective studies/by MaxTransdermal Estradiol Patches Show Promise as a Safer Alternative to Traditional Hormone Therapy in Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxTalazoparib Plus Enzalutamide in HRR-Deficient mCRPC: Final Overall Survival Results from TALAPRO-2
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxASCO GU 2025: Impact of Homologous Recombination Repair Alterations on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (BRCA, ATM, CDK12,…)
/0 Comments/in Observational, Retrospective studies/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastasis BRCA cancer immunotherapy cancer treatment chemotherapy clinical trial clinical trials crispr darolutamide diet drug discovery drug repurposing drug resistance enzalutamide gut microbiome hormone therapy HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic cancer metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics